Teva Pharmaceutical Industries: Number of Employees 2010-2024 | TEVA

Interactive chart of Teva Pharmaceutical Industries (TEVA) annual worldwide employee count from 2010 to 2024.
  • Teva Pharmaceutical Industries total number of employees in 2023 was 37,851, a 2.78% increase from 2022.
  • Teva Pharmaceutical Industries total number of employees in 2022 was 36,826, a 1.89% decline from 2021.
  • Teva Pharmaceutical Industries total number of employees in 2021 was 37,537, a 6.66% decline from 2020.
  • Teva Pharmaceutical Industries total number of employees in 2020 was 40,216, a 0.44% increase from 2019.
Teva Pharmaceutical Industries Annual Employee Count
2023 37,851
2022 36,826
2021 37,537
2020 40,216
2019 40,039
2018 42,535
2017 51,792
2016 56,960
2015 42,888
2014 43,000
2013 45,000
2012 45,948
2011 45,754
2010 39,660
2009 35,089
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.044B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00